19 source-based articles maintained by the HealthRX.com Editorial Team.
Showing 19 of 19 clinical reviews.
Semaglutide (Ozempic) 0.5-2.0 mg is being explored off-label for heart failure. Review the dosing protocol, trial evidence from SELECT and STEP-HFpEF, FDA-approved indications, and what clinicians should know.
A summary of the clinical trial evidence, off-label status, GRADE ratings, and practical considerations for using semaglutide (Ozempic 0.5 to 2.0 mg) in heart failure patients.
Semaglutide (Ozempic) is not FDA-approved for heart failure, but emerging trial data in HFpEF shows measurable benefits. Learn the evidence, monitoring protocols, and safety considerations for off-label use.
A clinical review of using semaglutide (Ozempic 0.5-2.0 mg) off-label for heart failure, including trial data, safety signals, and how it compares to FDA-approved HFpEF therapies.
Ozempic isn't FDA-approved for kidney protection, but the FLOW trial found a 24% drop in kidney failure risk. See dosing, UACR effects, and monitoring needs.
Ozempic kidney protection: the approved use in type 2 diabetes and CKD, FLOW trial results, weekly dosing, monitoring and evidence beyond diabetes.
Semaglutide (Ozempic) 0.5-2.0 mg is being studied for kidney protection in CKD. Review the off-label evidence, dosing protocols, FLOW trial results, and clinical guidance for renal use.
A clinical review of semaglutide (Ozempic) for kidney protection, including FLOW trial data, off-label considerations, dosing, risks, and what the evidence actually supports.
Clinical evidence review of off-label semaglutide (Ozempic 0.5-2.0 mg) for nonalcoholic steatohepatitis (NASH), including trial data, dosing, and guideline positioning.
Semaglutide (Ozempic) 0.5 to 2.0 mg is used off-label for NASH. Review the dosing protocol, key trial data, FDA status, and what clinicians should know before prescribing.
Semaglutide (Ozempic) is not FDA-approved for NASH/MASH, but clinical trial data shows histological improvement in liver fibrosis and steatohepatitis. Learn the risks, dosing, and evidence.
A guide to using semaglutide (Ozempic 0.5 to 2.0 mg) off-label for NASH, covering the evidence base, GRADE ratings, required monitoring, and what FDA approval means for this indication.
Semaglutide (Ozempic) is used off-label for PCOS to improve insulin resistance, restore ovulation, and reduce androgen levels. Learn the dosing protocol, evidence base, and what clinicians should discuss with patients.
A evidence summary of off-label semaglutide (Ozempic) for polycystic ovary syndrome (PCOS), covering trial data on weight, androgens, ovulation, and insulin resistance.
A deep dive into using semaglutide (Ozempic 0.5 to 2.0 mg) off-label for polycystic ovary syndrome. Covers the clinical evidence, GRADE ratings, FDA approval context, dosing, risks, and when to consider Wegovy or metformin instead.
Ozempic (semaglutide 0.5-2.0 mg) is FDA-approved for type 2 diabetes, not weight loss. Here's what the clinical trials show about off-label use, real risks, and how it compares to the approved weight-loss dose.
Ozempic (semaglutide 0.5 to 2.0 mg) is FDA-approved for type 2 diabetes, not weight loss. This guide covers the evidence, off-label dosing protocols, risks, and how it compares to FDA-approved Wegovy for weight management.
Ozempic (semaglutide 0.25-2.0 mg) is FDA-approved for type 2 diabetes but widely prescribed off-label for weight loss. Learn the evidence, proper monitoring, and clinical protocols.
A clinical evidence summary of off-label semaglutide (Ozempic 0.5 to 2.0 mg) for weight loss, including trial data, FDA status, dosing, and how it compares to on-label Wegovy.